anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Although it is clinically important, a reliable and economical solution to automatic seizure detection for patients at home is yet to be developed. Traditional algorithms rely on multi-channel EEG signals and features of canonical EEG power description. This study is aimed to propose an effective single-channel EEG seizure detection method centered on novel EEG power parameterization and channel selection algorithms. We employed the publicly available multi-channel CHB-MIT Scalp EEG database to gauge the effectiveness of our approach. We first adapted a power spectra parameterization algorithm to characterize the aperiodic and periodic components of the ictal and inter-ictal EEGs. We selected four features based on their statistical significance and interpretability, and developed a ranking approach to channel selection for each patient. We then tested the effectiveness of our approaches to channel and feature selection for automatic seizure detection using support vector machine (SVM) as the classifier. The performance of our algorithm was evaluated using five-fold cross-validation and compared to those methods of comparable complexity (using one or two channels of EEG), in terms of accuracy, specificity, sensitivity, precision and F1 score. Some channels of EEG signals show strikingly different distributions of PSD features between the ictal and inter-ictal states. Four features including the offset and exponent parameters for the aperiodic component and the first and second highest total power (TPW1 and TPW2) form the basis of channel selection and the input of SVM classifier. The selected channel is found to be patient-specific. Our approach has achieved a mean sensitivity of 95.6%, specificity of 99.2%, accuracy of 98.6%, precision of 95.5%, and F1 score of 95.5%. Compared with algorithms in previous studies that used one or two channels of EEG signals, ours outperforms in specificity and accuracy with comparable sensitivity. EEG power spectra parameterization to feature extraction and feature ranking-based channel selection are found to enable efficient and effective automatic seizure detection based on single-channel EEG signal.
Circadian rhythms play a pivotal role in governing various physiological processes, including physical performance. However, in individuals deprived of light perception, such as the blind, these circadian rhythms face disruption. This study aimed to explore the influence of disturbed circadian rhythms on short-term maximal physical performance in children and adolescents with visual impairment. Forty-five volunteers participated in this study, comprising 17 blind, 13 visually impaired, and 15 sighted participants. The participants underwent a series of tests assessing maximal isometric strength performance across two days. To mitigate the influence of morning session fatigue on the evening results, each participant group performed in two separate testing sessions (i.e. in the morning (7:00 h) and in the evening (17:00 h)) on non-consecutive days in a randomized and counterbalanced setting, with approximately 36 h of recovery time between sessions. To mitigate the impact of inter-individual differences on mean values and to account for the influence of age and sex on the studied variables, data were normalized. The outcomes revealed a significant diurnal variation in maximal isometric strength performance among sighted individuals, with peak performance observed in the evening. This pattern aligns with their well-entrained circadian rhythm. In contrast, blind and visually impaired individuals did not display significant diurnal variation, signaling disrupted circadian rhythms due to the absence of light perception. These findings emphasize the crucial consideration of circadian rhythms in assessments of physical performance, especially among participants with visual impairments.
Operability in measuring a Cobb angle of a vertebra image is improved and erroneous diagnosis is prevented. A vertebra image having a plurality of curved portions is displayed on the monitor screen of a display section and auxiliary lines are drawn along the axial directional upper end of a superior end vertebra and the axial directional lower end of an inferior end vertebra of each curved portion based on manipulation through an operational section. At that time, drawing of the individual auxiliary lines is permitted only in a sequence along the head-to-tail direction of the vertebra image displayed on the monitor screen. Then, an angle defined by two auxiliary lines adjoining in the drawing sequence (head-to-tail directional sequence) of the individual auxiliary lines is measured as a Cobb angle. When one of the auxiliary lines is shifted, the individual auxiliary lines are ordered in a shorter-to-longer sequence of the distance from one side equivalent to a head-side end portion of the image based on positional information of each auxiliary line after shifting. Then, an angle defined by two auxiliary lines adjoining in the ordered sequence is measured again as a Cobb angle.
Participants will receive methylnaltrexone bromide (MNTX) 450 milligrams (mg) (3 tablets of 150 mg each) once daily (QD) orally. Treatment will continue until participant's death or early withdrawal from the study or study termination by the sponsor.
Lung adenocarcinoma (LUAD) remains one of the most aggressive tumors and the efficacy of conventional treatment has been bleak. Nowadays, gene-targeted therapy has become a new favorite in tumor therapy. Herein, we investigated the effect of platelet derived growth factor BB (PDGFBB) on LUAD. Firstly, PDGFBB was upregulated in LUAD patients and closely linked with poor survival. Furthermore, the expression of PDGFBB and PDGFRα/β in LUAD cells was higher than that in normal lung cells. By loss-of-function with herpes simplex virus (HSV)-PDGFi-shRNA, we found that PDGFBB knockdown caused a significant decrease in proliferation and migration, but evoked apoptosis of LUAD cells in vitro. Conversely, exogenous PDGFBB held adverse effect. Additionally, A549 cells with PDGFBB knockdown had a low probability of tumorigenesis in vivo. Moreover, PDGFBB knockdown restrained the growth of xenografts derived from normal A549 cells. Mechanistically, PDGFBB knockdown suppressed PI3K/AKT and Ras/MAPK signaling, while PDGFBB was the opposite. Therefore, we concluded that PDGFBB might facilitate the tumorigenesis and malignancy of LUAD through its functional downstream nodes-PI3K/AKT and Ras/MAPK signaling, which supported that PDGFBB could serve as a rational therapeutic target for LUAD.
Accumulating evidence indicates that the dysregulation of microRNAs (miRNAs or miRs), is associated with human malignancies and suggests a casual role of miRNAs in tumor initiation and progression. Even though it has been discovered that a number of miRNAs play significant parts in the development of colorectal cancer (CRC), it is crucial to comprehend the regulatory functions that other miRNAs play in CRC. Based on GSE183437 and GSE156719 microarray data that were obtained from Gene Expression Omnibus database, candidate miRNAs were researched. The oncogenic effects of miR‑25‑3p in different malignancies have led to its selection for additional investigation in the present study. The expression of miR‑25‑3p was verified by reverse transcription‑quantitative PCR, and its correlation with clinicopathological characteristics in patients with CRC was then investigated. In vitro assays were conducted to investigate the influence of miR‑25‑3p on the proliferative and apoptotic behaviors of HCT116 and Caco‑2 cells. The present data revealed that miR‑25‑3p exhibited one of the most significant upregulations in CRC tissues and cell lines. The expression levels of miR‑25‑3p were found to be intimately correlated with tumor size, distant metastasis, tumor‑node‑metastasis stage, and shorter overall survival rate. In terms of functionality, the downregulation of miR‑25‑3p led to the inhibition of cellular proliferation and the enhancement of apoptosis in both HCT116 and Caco‑2 cell lines. The critical tumor suppressor F‑box and WD repeat containing domain 7 (FBXW7) was identified as a direct molecular target for miR‑25‑3p, with an inverse relationship observed between the two in neoplastic tissues. Subsequent studies demonstrated that the tumor suppressive effects of miR‑25‑3p inhibitor were effectively negated by the silencing of FBXW7. Moreover, the ability of FBXW7 to inhibit the expression of several oncogenes was deemed essential for countering the anticancer effects mediated by miR‑25‑3p downregulation. These findings posit miR‑25‑3p as a promising therapeutic target and prognostic indicator for CRC.
Two-vial presentation of ID93 + GLA-SE. Participants will receive two intramuscular (IM) injections of the vaccine on Days 0 and 56. 2 mcg ID93 and 5 mcg GLA-SE in 0.5 mL volume will be given per injection.
Lithium carbonate, 250mg/tablet. The dose starts with three times a day and one tablet each time for a week. The daily dose will then be adjusted according to serum lithium level and clinical finding. Target serum lithium level is 0.6 - 1.2mmol/L.
OBJECTIVES: To assess the feasibility of using a seizure recurrence prediction tool in a First Seizure Clinic, considering (1) the accuracy of initial clinical diagnoses and (2) performance of automated computational models in predicting seizure recurrence after first unprovoked seizure (FUS).
METHODS: To assess diagnostic accuracy, we analysed all sustained and revised diagnoses in patients seen at a First Seizure Clinic over 5 years with 6+ months follow-up ('accuracy cohort', n = 487). To estimate prediction of 12-month seizure recurrence after FUS, we used a logistic regression of clinical factors on a multicentre FUS cohort ('prediction cohort', n = 181), and compared performance to a recently published seizure recurrence model.
RESULTS: Initial diagnosis was sustained over 6+ months follow-up in 69% of patients in the 'accuracy cohort'. Misdiagnosis occurred in 5%, and determination of unclassified diagnosis in 9%. Progression to epilepsy occurred in 17%, either following FUS or initial acute symptomatic seizure. Within the 'prediction cohort' with FUS, 12-month seizure recurrence rate was 41% (95% CI [33.8%, 48.5%]). Nocturnal seizure, focal seizure semiology and developmental disability were predictive factors. Our model yielded an Area under the Receiver Operating Characteristic curve (AUC) of 0.60 (95% CI [0.59, 0.64]).
CONCLUSIONS: High clinical accuracy can be achieved at the initial visit to a First Seizure Clinic. This shows that diagnosis will not limit the application of seizure recurrence prediction tools in this context. However, based on the modest performance of currently available seizure recurrence prediction tools using clinical factors, we conclude that data beyond clinical factors alone will be needed to improve predictive performance.
The goal of the proposed study is to gather preliminary feasibility and efficacy data for an innovative intervention (Narrative Exposure Therapy: NET) to promote adolescent mental health related to interpersonal trauma (IPT). Among those at highest risk for interpersonal violence and its sequelae are youth from urban, low-resourced neighborhoods. Post-traumatic stress disorder (PTSD) is a common outcome associated with IPT. Substance misuse (SUB) is a frequent concomitant of PTSD. NET is a promising intervention to reduce PTSD symptoms and associated psychological distress, via the supported reconstruction (narrative telling) of the traumas. NET has a critical advantage over existing PTSD treatments in that it can be delivered in a brief format, in community settings where at-risk adolescents are likely to be found. Despite its promise in treating adolescent distress, NET has yet to be tested as an intervention for those who have interpersonal trauma-related PTSD. Further NET's influence on SUB has not been examined.

Accordingly, the objective of this project is to conduct a pilot study (N=30) to estimate NET treatment effects on PTSD symptoms and SUB in IPT-exposed urban adolescents (ages 16-21). Both feasibility and preliminary efficacy data will be collected to serve as pilot work for a larger-scale NIH proposal. Recruitment and intervention will be set within community partners where the adolescents already are connected and are receiving social or psychological services. Outcome data will be collected at: (T0) Baseline, and at 1(T1), and 3 months (T2) follow-up assessments. Participant responses to the intervention will be assessed post-intervention. Change in PTSD, SUB will be estimated with effect sizes and inferential tests. Preliminary evidence of efficacy and feasibility will pave the way for further NET development to offer a patient-oriented, community-based, intervention that will promote adolescent mental health for those at greatest risk for health access and outcomes disparities.
Measures of tongue function were collected from two groups of individuals(healthy adults and stroke patients with dysphagia ). The items of measurement about healthy adults are the maximal tongue pressure, tongue endurance, and lingual swallowing pressures of saliva, 3-ml water, IDDSI 2, IDDSI3, and IDDSI 4 liquids.
The invention discloses a method, a device and a system for extracting time compound words from medical texts, and particularly relates to the technical field of natural language processing information extraction. The invention comprises a reading module, a calculating module and a display module. The reading module mainly refers to a system for reading medical texts. The calculation module comprises a time compound word extraction unit, a time compound word updating unit and a new time compound word structure extraction unit. The extraction of the time compound words is mainly based on the word formation method of 'number words + time collocation words', and partial time compound word structures need to be manually summarized. The method comprises the following steps: a. reading the medical text; b. extracting time compound words through a time compound word structure; c. and acquiring a time compound word structure through the time compound word. If the result is increased in number compared with the existing entities, the iteration is continued, otherwise, the iteration is ended. The display module includes: a storage unit and an output unit. The method takes the medical text as a starting point, and finally realizes the accurate extraction of the time compound words in the medical text.
To overcome the difficulties inherent in conventional treatment planning approaches, new techniques are described herein for providing an intuitive user interface for automatic structure derivation in patient modeling. In an embodiment, a graphical user interface is provided that provides a list of structures of a specified region. The interface uses medical terminology instead of mathematical one. In one or more embodiments, the list of structures may be a pre-defined list of structures that correspond to that region for the purposes of treatment planning. A user is able to actuate a toggle to include and/or exclude each of the structures separately. In one or more embodiments, the user is also able to actuate a toggle to define a perimeter around each included structure, and further define a margin around the perimeter. The user is also able to specify whether the desired output should include a union or the intersection of all included structures.
Selective serotonin reuptake inhibitors (SSRIs) are widely used for depression based on the monoamine deficiency hypothesis. However, the clinical use of these agents is controversial, in part because of their variable clinical efficacy and in part because of their delayed onset of action. Because of the complexities involved in replicating human disease and clinical dosing in animal models, the scientific community has not reached a consensus on the reasons for these phenomena. In this work, we create a theoretical hippocampal model incorporating escitalopram's pharmacokinetics, pharmacodynamics (competitive and non-competitive inhibition, and serotonin transporter (SERT) internalization), inflammation, and receptor dynamics. With this model, we simulate chronic oral escitalopram in mice showing that days to weeks are needed for serotonin levels to reach steady-state. We show escitalopram's chemical efficacy is diminished under inflammation. Our model thus offers mechanisms for how chronic escitalopram affects brain serotonin, emphasizing the importance of optimized dose and time for future antidepressant discoveries.
Persistent Post-Surgical Pain (PPSP) after Video Assisted Thoracic Surgery (VATS) lobectomy procedures is an important health problem for which there is no effective method of prevention. NMDA antagonists and steroids can modify pain signaling-sensitization pathways, and inflammatory-immune pathways, and hence can potentially prevent the development of PPSP. These agents have been safely used in thoracic surgeries to obtain many perioperative benefits, without increasing the harmful effects. Since these agents act by different biological mechanisms, it is appropriate to study their effects in a factorial design to increase the trial efficiency. Before conducting a large multicenter trial, we propose to establish the feasibility by carrying out this feasibility trial.

The objective of the PAIN-STOP trial is to assess the feasibility of a larger randomized controlled trial (RCT) evaluating NMDA antagonists and IV steroids, as compared to placebo, in decreasing the chances of clinically significant persistent post-surgical pain (PPSP) after video assisted thoracoscopic surgeries (VATS). This is a multi-centre randomized, controlled clinical trial with a 2 x 2 factorial design. The pilot phase of the trial will recruit 48 patients and follow them for 3 months. Patients will be randomized to one of four groups: 1) NMDA active + Steroid placebo; 2) Steroid active + NMDA placebo; 3) NMDA active + Steroid active; 4) NMDA placebo + Steroid placebo. Follow-up visit will be conducted in hospital; day 8 and month 2 by a phone call; and in person follow-up visits at 30 days and 3 months post-randomization; for patients who cannot attend in person, a telephone follow up will be done.
PURPOSE: An anti-obesity composition containing (1S,2S,3S,4S)-5-aminocyclopentane-1,2,3,4-tetraol is provided to suppress differentitation of adipocyte precursor cells and to prevent or treat obesity or obesity-associated diseases. CONSTITUTION: An anti-obesity composition contains a compound of chemical formula 1 as an active ingredient. A pharmaceutical composition for preventing or treating obesity contains the composition as an active ingredient. The pharmaceutical composition is used in the form of tablet, pill, powder, granule, capsule, suspension, emulsion, syrup, sterilized solution, insoluble solvent, suspension, or suppository. A food composition for preventing or treating obesity contains the composition as an active ingredient. The food composition is meat, sausage, bread, chocolate, candy, ramen, gums, ice creams, tea, drink, or vitamin.
Teclistamab (Tec) is a first-in-class BCMA × CD3 bispecific T-cell engager antibody approved for treating multiple myeloma progressing after at least 4 lines of therapy. The objective of this study was to evaluate the rate of cytokine release syndrome (CRS) in patients who were treated with commercial Tec and had prior exposure to other T-cell redirection therapies. A retrospective chart review was performed to identify patients who completed the Tec step-up dosing phase between November 2022 and November 2023. Patients were divided into 2 cohorts based on prior exposure to T-cell redirection therapy (cohort 1: T-cell redirection therapy experienced; cohort 2: T-cell redirection therapy naïve). The primary objective was to compare the differences in the rates of CRS between the 2 cohorts. Univariate and multivariate logistic regression analyses were performed to assess the association between CRS rates with Tec and prior treatment with T-cell redirection therapy. A total of 72 patients were included in the analysis (27 in cohort 1 and 45 in cohort 2). The CRS rates were significantly lower in cohort 1 (37%, n = 10) compared with cohort 2 (80%, n = 36; P = .0004). Based on multivariate logistic regression analysis, patients without prior exposure to T-cell redirection therapy (cohort 2) had about a fourfold increase in the incidence of CRS (95% confidence interval, 1.40-14.90; P = .0002) with Tec. In our study, prior exposure to T-cell redirection therapy reduced the risk of CRS with Tec during the step-up dosing phase. This observation will allow for the optimization of CRS prophylactic strategies for Tec.
The research was conducted on participants over the age of 65 with urinary incontinence living in a nursing home. After these participants were informed about the content of the study, a signed informed consent form will be obtained. This study is an assessor-blinded, randomized controlled trial. Participants with incontinence aged 65 and over living in a nursig home were randomly assigned to intervention (IG) and control group (CG). The intervention group attended an exercise program that included Otago exercises combined with pelvic floor muscle training (PFMT). The control group was included in the PFMT program with different positions. Duration of exercise for both groups was 45-60 minutes per session three times a week for 12 weeks. Incontinence symptoms and severity (Pelvic Floor Distress Inventory-20, bladder diary), PFM muscle function (superficial electromyography), balance (Berg Balance Scale), functional status (Senior Fitness Test) and fear of falling (Falls Efficacy Scale) was measured at baseline and after the intervention.
1. A liquid composition for oral use containing a calcium compound and an acidulant characterised in that calcium is present in the range of 0.3 to 0.55 mol per mol of acid and that the proportion of calcium and acidulant in the composition is selected so that the pH of the composition is from 3.5 to 4.5. 2. A composition as claimed in claim 1 in which the calcium is present in an amount of at least 0.4 mol per mol of acid. 3. A composition as claimed in claim 1 or 2 in which the pH of the composition is not more than 4. 4. A composition as claimed in any one of claims 1 to 3 in which the pH is from 3.7 to 3.9. 5. A composition as claimed in any one of claims 1 to 4 in which the acid is citric acid or malic acid or lactic acid or mixtures thereof. 6. A composition as claimed in any one of claims 1 to 5 in which the calcium compound is calcium carbonate, calcium hydroxide, calcium citrate, calcium malate, calcium lactate, calcium chloride, calcium glycerophosphate or calcium formate. 7. A composition as claimed in any one of claims 1 to 6 which is a beverage. 8. A composition as claimed in claim 7 in which the beverage is a still fruit drink, or a carbonated soft drink or a health drink. 9. A composition as claimed in claim 8 in which the health drink is a blackcurrant juice drink or a vitamin added beverage. 10. A composition as claimed in any one of claims 1 to 6 which is a drink concentrate for the preparation of a beverage. 11. A composition as claimed in claim 10 which is a concentrate for a fruit drink or health drink. 12. A composition as claimed in any one of claims 1 to 6 which is an oral healthcare composition. 13. A composition as claimed in claim 12 which is a mouthwash.
In cycle 1, subjects in sequence A receive a 50-mg single dose of TLL-018 extended-release tablet on day 1, and once daily for 5 consecutive days from day 3 onwards. After a 3-day washout period, subjects enter the cycle 2 at day 11 when they receive a 20-mg single dose of TLL-018 immediate-release tablet on the morning and another dose 12 hours later at night. From day 13 onward, they continue to receive 20 mg TLL-018 immediate-release tablets twice daily for 5 consecutive days.